Digg It - Business

November Billing Performance Index (BPI) outperformed October value by 30%, replacing one participant in the list of top ten performers and raising the index from 17.8 up to 13.7. This article

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

describes a sixth iteration of a prototype for a rule-based chiropractic billing index, including its coverage definition, update cycle, volume weighting, and provided information.

BPI = 13.7 mean

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

that the average of ten top performing payers working with BillingPrecision.com clients have 13.7% of Accounts Receivable beyond 120 days. BPI is a key billing performance characteristic, as it i

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

s a proxy of the claims that are never paid. Obviously, the lower is the index the better is billing performance. The table below also lists the top ten performing payers and their relative index

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

as recorded in Billing Precision's system.

Billing Precision Index 13.7
Blue Cross Blue Shield Wisconsin 2.9 (up from 6.9 in October)
Blue C

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

oss Blue Shield Illinois 5.4 (up from 7.1 in October)

Horizon 6.5 (down from 3.7 in October)

Cigna 12 (up from 12.2 in October)

United Health Care 12.1

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

(down from 11.7 in October)

Medicare New Jersey 12.1 (down from 10.8 in October)

Medicare Wisconsin 16.1 (up from 19.2 in October)

Aetna 17.2 (up from 20.1

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

n October)

Health EOS 19.5

Blue Cross Blue Shield New Jersey 20.2 17.7 (down from 17.7 in October)

Dropped participant from October BPI:

Blue Cr

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

ss Blue Shield Florida 44.6

Improved participants with respect to October BPI:

Blue Cross Blue Shield Wisconsin 2.9 (up from 6.9 in October)
Blue Cross Blue S

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

hield Illinois 5.4 (up from 7.1 in October)

Cigna 12 (up from 12.2 in October)

Medicare Wisconsin 16.1 (up from 19.2 in October)

Aetna 17.2 (up from 20.1

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

n October)

Underperforming participant with respect to October BPI:

Horizon 6.5 (down from 3.7 in October)
United Health Care 12.1 (down from 11.7 in Octob

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

Medicare New Jersey 12.1 (down from 10.8 in October)

New participant with respect to October BPI:

Health EOS 19.5

Coverage

BPI is

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

rule-based, i.e., payer participation in the index is defined by dynamically rules at the time of computation and not by a static listing of specific payers. Therefore, any specific payer may star

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

or discontinue participation in the index, dependent on satisfaction of rule's conditions.

Current selection of payers for participation in the BPI is based on fifty top-volume providers across a

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

l United States that have received Billing Precision services for more than six months and have more than two hundred claims in their current Accounts Receivable.

Update Cycle

BillingPre

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

cision.com updates BPI on a monthly basis.

Volume Weighting

BPI is volume weighted, which is important to accommodate future growth of provided information, index combinations, and sensi

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

ivity across multiple indices.

Information Provided

BPI computes the percent of Accounts Receivable beyond 120 days. Note that national average across all medical specialties of percent

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

of accounts receivable beyond 120 days is 17.7%.

Summary

Medical Billing Performance Index helps the development of billing industry standards. Medical service providers can use the ind

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

ex to benchmark their billing performance and to guide its improvement over time. Rule-based index definition allows for automated inclusion and exclusion of payers in the index based on payer att

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

ibutes, such as numbers of processed claims, accounts receivable distribution, certain mix of CPT codes, or patient demographics. Relative payer index provides billing process improvement direction

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.diggit.org.ua/article/32657/diggit-Outsourced-Chiropractic-Office-Billing-Service-Performance-Benchmark--November-2006.html">Outsourced Chiropractic Office Billing Service Performance Benchmark - November 2006</a>

BB link (for phorums):
[url=http://www.diggit.org.ua/article/32657/diggit-Outsourced-Chiropractic-Office-Billing-Service-Performance-Benchmark--November-2006.html]Outsourced Chiropractic Office Billing Service Performance Benchmark - November 2006[/url]

It is important for you to constantly advertise even after you have established your clientele. Today you may have a client and tomorrow the client could go out of business.

Does the signage in your company make people do a double take? Do they look back to see what it says? Does it spark curiosity in the viewer? What I am asking is; does your company have a signage double-take strategy to capture the mind and attention of your future customers?

This is a true story of three cats, a new baby, a new house, and a new hierarchy.

Tags

Links

Digg It - Outsourced Chiropractic Office Billing Service Performance Benchmark - November 2006

Related Articles: